Specialized immunological studies in the diagnostics of idiopathic infertility and recurrent miscarriages have limited applicability, as the role of the immune system in these conditions is not thoroughly understood. In ovulatory cycles, changes occur in the populations of uterine lymphocytes, which may influence the receptivity of the endometrium and the implantation of the embryo. Particularly notable are the changes in natural killer (NK) cells, which reach their peak during the luteal phase and regulate the invasion of the trophoblast. The dominant NK cells exhibit a CD56bright phenotype and differ in cytokine profiles from peripheral blood cells. Cyclical changes also affect macrophages and T lymphocytes; however, it is unclear whether their proportions differ in women with reduced fertility. There is a need to investigate how the composition of lymphocytes in blood influences the populations in the endometrium. The aim of this study is to analyze the correlation between peripheral and endometrial lymphocytes in women with idiopathic infertility and recurrent miscarriages, compared to fertile women.
Age range
18 Years – 45 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Assessment of the percentage of Non-classical monocytes CD16++/ CD14- (% monocytes) in peripheral blood
Timeframe: up to 6 months
Assessment of the percentage of Intermediate monocytes CD16+/CD14+ (% monocytes) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of Classical monocytes CD16-/CD14++ (% monocytes) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of plasmocytes (% leukocytes) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of Macrophages M1/M2 CD163+/CD206- (% monocytoid cells) ratio in peripheral blood
Timeframe: up to 6 months
Assessment of the percentage of CD3+ lymphocytes (% lymphocytes) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of B lymphocytes (% lymphocytes) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of Total NK (% lymphocytes) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of NK CD56++/CD16- (% NK) in peripheral blood
Timeframe: up to 6 months
Assessment of the percentage of NK CD56+/CD16+ (% NK) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of NK CD56+/CD16++ (% NK) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of NK CD56-/CD16++ (% NK) in peripheral blood by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of Non-classical monocytes CD16++/ CD14- (% monocytes) in endometrium by flow cytometry
Timeframe: up to 6 months
ssessment of the percentage of Intermediate monocytes CD16+/CD14+ (% monocytes) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of Classical monocytes CD16-/CD14++ (% monocytes) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the ratio of Macrophages M1/M2 CD163+/CD206- (% monocytoid cells) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of plasmocytes (% leukocytes) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of CD3+ lymphocytes (% lymphocytes) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of B lymphocytes (% lymphocytes) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of Total NK (% lymphocytes) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of NK CD56++/CD16- (% NK) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of NK CD56+/CD16+ (% NK) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of NK CD56+/CD16++ (% NK) in endometrium by flow cytometry
Timeframe: up to 6 months
Assessment of the percentage of NK CD56-/CD16++ (% NK) in endometrium by flow cytometry
Timeframe: up to 6 months